UBS lowered the firm’s price target on Celldex (CLDX) to $38 from $44 and keeps a Buy rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDX:
- 3 Best Stocks to Buy Now, 5/9/2025, According to Top Analysts
- Celldex: Strong Financials and Promising Clinical Developments Support Buy Rating
- Celldex price target lowered to $50 from $80 at H.C. Wainwright
- Celldex’s Promising Pipeline and Strong Financial Position Justify Buy Rating
- Celldex reports Q1 EPS (81c), consensus (74c)